100 day autologous stem cell transplant survival rate trial#

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. 2007 13:183–96.Īttal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, et al. NCCN guidelines insights: multiple myeloma, version 1.2020. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, et al.

100 day autologous stem cell transplant survival rate update#

Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. 2020 7:e370–e80.Ĭhari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al.

100 day autologous stem cell transplant survival rate plus#

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. ASCT is safe and efficacious in carefully selected MM patients aged 75 or above and we believe that age should not be an exclusion factor for ASCT in MM.Īttal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. One patient died within 100 days of transplant representing a 2% 100-day mortality rate. Median overall survival and progression free survival for the cohort were 82 months and 33 months, respectively. Overall response rate was 100% with a complete response seen in 57% of patients. Reasons for hospitalization included fever or infection (32%), cardiac arrhythmia (36%), and dehydration (32%). 48% of patients completed the ASCT without requiring hospitalization and 52% ( n = 26) of patients required hospitalization with a median duration of hospital admission of 9 days (IQR 5–13). received reduced intensity conditioning with melphalan 140 mg/m 2. Median time from diagnosis to ASCT was 6.85 months (IQR 5.2–10.52) and 50%. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65.